---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-004266"
form_type: "8-K"
ticker: "ULBI"
cik: "0000875657"
company_name: "ULTRALIFE CORP"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:46:09.001937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03

## Summary
- Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.
- Q4 operating income $3.6M vs $0.2M; full-year $9.5M vs $0.1M.
- Q4 adjusted EPS $0.18 vs loss of $0.03; full-year adjusted EPS $0.52 vs loss of $0.07.
- Medical battery sales highest quarter ever; Battery & Energy gross margin expanded 360 bps to 25.2%.
- Backlog $103.5M at year-end; management plans to pay down acquisition debt.

## SEC filing metadata
- accession: 0001437749-24-004266
- form_type: 8-K
- ticker: ULBI
- cik: 0000875657
- company_name: ULTRALIFE CORP
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/ulbi20240214_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-004266
- JSON: https://secwatch.observer/filing/0001437749-24-004266.json
- Plain text: https://secwatch.observer/filing/0001437749-24-004266.txt

## Key facts
- Earnings Releases
  ULTRALIFE CORP reported full year ended December 31, 2023 results: revenue $158.6 million, EPS Adjusted EPS of $0.52.
  - Period: full year ended December 31, 2023
  - Revenue: $158.6 million
  - EPS: Adjusted EPS of $0.52
  - Result: reported results
  source text: representing a 134.8% year-over-year increase ● Backlog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: ● Sales of $158.6 million representing a 20.3% year-over-year increase ● Operating income of $9.5 million versus $0.1 million for 2022 ● Adjusted EPS of $0.52 compared to a loss of $0.07 for 2022 ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm
- Earnings Releases
  ULTRALIFE CORP reported fourth quarter ended December 31, 2023 results: revenue $44.5 million, net income $2.9 million, EPS $0.17 per diluted share.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $44.5 million
  - Net income: $2.9 million
  - EPS: $0.17 per diluted share
  - Result: reported results
  source text: 15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $3.6 million versus $0.2 million for the 2022 fourth
  evidence_url: https://www.sec.gov/Archives/edgar/data/875657/000143774924004266/0001437749-24-004266-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.